Treatment of dyslipidemia in patients with type 2 diabetes

被引:78
作者
Vijayaraghavan, Krishnaswami [1 ]
机构
[1] Scottsdale Healthcare Res Inst, Div Cardiovasc, Scottsdale, AZ USA
关键词
BILE-ACID SEQUESTRANTS; EXTENDED-RELEASE NIACIN/LAROPIPRANT; DENSITY-LIPOPROTEIN CHOLESTEROL; IMPROVES GLYCEMIC CONTROL; CORONARY-HEART-DISEASE; LDL CHOLESTEROL; RISK-FACTORS; COLESEVELAM HYDROCHLORIDE; CARDIOVASCULAR-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA;
D O I
10.1186/1476-511X-9-144
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Type 2 diabetes is associated with significant cardiovascular morbidity and mortality. Although low-density lipoprotein cholesterol levels may be normal in patients with type 2 diabetes, insulin resistance drives a number of changes in lipid metabolism and lipoprotein composition that render low-density lipoprotein cholesterol and other lipoproteins more pathogenic than species found in patients without type 2 diabetes. Dyslipidemia, which affects almost 50% of patients with type 2 diabetes, is a cardiovascular risk factor characterized by elevated triglyceride levels, low high-density lipoprotein cholesterol levels, and a preponderance of small, dense, low-density lipoprotein particles. Early, aggressive pharmacological management is advocated to reduce low-density lipoprotein cholesterol levels, regardless of baseline levels. A number of lipid-lowering agents, including statins, fibrates, niacin, and bile acid sequestrants, are available to target normalization of the entire lipid profile. Despite use of combination and high-dose lipid-lowering agents, many patients with type 2 diabetes do not achieve lipid targets. This review outlines the characteristics and prevalence of dyslipidemia in patients with type 2 diabetes and discusses strategies that may reduce the risk of cardiovascular disease in this population.
引用
收藏
页数:12
相关论文
共 92 条
[1]   Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (07) :1225-1236
[2]   Diabetic dyslipidaemia [J].
Adiels, Martin ;
Olofsson, Sven-Olof ;
Taskinen, Marja-Riitta ;
Boren, Jan .
CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (03) :238-246
[3]   Standards of Medical Care in Diabetes-2009 [J].
不详 .
DIABETES CARE, 2009, 32 :S13-S61
[4]   The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment [J].
Andrikoula, M. ;
McDowell, I. F. W. .
DIABETES OBESITY & METABOLISM, 2008, 10 (04) :271-278
[5]  
[Anonymous], AV ROS MAL TABL PRES
[6]  
[Anonymous], 2005, NAT DIAB FACT SHEET
[7]  
[Anonymous], ACTOS PIOGL HYDR TAB
[8]   Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring effective reductions in cholesterol using rosuvastatin therapY (MERCURY) II [J].
Ballantyne, Christie M. ;
Bertolami, Marcelo ;
Garcia, Rugo Ricardo Hernandez ;
Nul, Daniel ;
Stein, Evan A. ;
Theroux, Pierre ;
Weiss, Robert ;
Cain, Valerie A. ;
Raichlen, Joel S. .
AMERICAN HEART JOURNAL, 2006, 151 (05) :975.e1-975.e9
[9]   Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial [J].
Ballantyne, CM ;
Houri, J ;
Notarbartolo, A ;
Melani, L ;
Lipka, LJ ;
Suresh, R ;
Sun, S ;
LeBeaut, AP ;
Sager, PT ;
Veltri, EP .
CIRCULATION, 2003, 107 (19) :2409-2415
[10]   Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) [J].
Bays, Harold E. ;
Bazata, Debbra D. ;
Clark, Nathaniel G. ;
Gavin, James R., III ;
Green, Andrew J. ;
Lewis, Sandra J. ;
Reed, Michael L. ;
Stewart, Walter ;
Chapman, Richard H. ;
Fox, Kathleen M. ;
Grandy, Susan .
BMC PUBLIC HEALTH, 2007, 7 (1)